Natera, INC Form 4 insider transactions

Natera CEO Steven Leonard Chapman acquired 36,682 Restricted Stock Units (RSUs) on January 31, 2025, which vest over four years.

Natera's CFO, Michael Brophy, reports the acquisition of restricted stock units and the sale of common stock under a pre-arranged trading plan.

Jonathan Sheena, co-founder of Natera, Inc., reports the acquisition of 3,549 Restricted Stock Units (RSUs) vesting over four years, according to a Form 4 filing.

Matthew Rabinowitz, Executive Chairman of Natera, Inc., reports the acquisition of restricted stock units and updates to his beneficial ownership.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., reports the acquisition of restricted stock units.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., reports the acquisition of 12,720 shares of common stock through restricted stock units (RSUs) vesting over four years.

John Fesko, President and Chief Business Officer of Natera, Inc., reports the acquisition of 11,832 Restricted Stock Units (RSUs) on January 31, 2025.

Director Herm Rosenman acquired 133 Restricted Stock Units (RSUs) of Natera, Inc. in lieu of quarterly retainer fees.

Director James Healy reports the acquisition of 114 Restricted Stock Units (RSUs) from Natera, Inc. in lieu of quarterly retainer fees.

Director Roelof Botha acquired 151 shares of Natera, Inc. common stock through the issuance of fully vested RSUs in lieu of quarterly retainer fees.

Director Roy D. Baynes acquired 92 shares of Natera, Inc. common stock through the issuance of fully vested Restricted Stock Units (RSUs) in lieu of quarterly retainer fees.

Natera's Chief Financial Officer, Michael Brophy, sold a total of 6,221 shares of common stock across multiple transactions to cover tax obligations and under a pre-arranged trading plan.

Natera co-founder Jonathan Sheena sold a total of 1,217 shares of common stock across three transactions to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Natera's Executive Chairman, Matthew Rabinowitz, sold a portion of his shares to cover tax obligations related to vesting Restricted Stock Units (RSUs).

A Natera executive, Daniel Rabinowitz, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

A Natera executive, Solomon Moshkevich, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

A Natera executive, John Fesko, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Natera's CEO, Steven Leonard Chapman, sold shares to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Natera co-founder Jonathan Sheena reported a charitable donation of 588 common stock shares on January 27, 2025.

Natera's Chief Financial Officer, Michael Burkes Brophy, sold 1,442 shares of common stock at $161.87 per share on January 27, 2025, under a pre-arranged 10b5-1 trading plan.

Natera's Chief Financial Officer, Michael Brophy, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

A Natera executive, John Fesko, sold shares to cover tax obligations related to vesting of restricted stock units.

Natera's co-founder recently exercised stock options and sold a portion of shares to cover tax obligations, according to a recent SEC filing.'

Natera's SEC. AND CHIEF LEGAL OFFICER, Daniel Rabinowitz, reports the acquisition and sale of company stock and restricted stock units.

Natera CEO Steven Chapman sold 78,553 shares of common stock to cover tax obligations after the vesting of restricted stock units.

Natera's Chief Financial Officer, Michael Brophy, sold shares to cover tax obligations following the vesting of restricted stock units.

Natera co-founder Jonathan Sheena reports the vesting of restricted stock units and subsequent acquisition of common stock on January 16, 2025.

Daniel Rabinowitz, Natera's SEC. AND CHIEF LEGAL OFFICER, reported the vesting of restricted stock units and subsequent acquisition of common stock on January 16, 2025.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, acquired a total of 48,548 shares of common stock through the vesting of performance-based Restricted Stock Units (RSUs).